Quality of Life in Sarcoidosis: Comparing the Impact of Ocular and Non-ocular Involvement of the Disease

REFERENCES

• Curtis JR BS. Examining the link between sarcoidosis and depression. Am J Respir Crit Care Med. 2001;163(2):306–308.
   PubMedGoogle Scholar
• Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax. January 1, 2005;60(1):32–38.
   PubMedGoogle Scholar
• De Vries J, Drent M. Quality of life and health status in sarcoidosis: a review. Semin Respir Crit Care Med. 2007;28(1):121–127.
   PubMedGoogle Scholar
• Gvozdenovic BS, Ilic-Dudvarski A, Zugic V, Judson MA. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respiratory Medicine. 2008;102(11):1636–1642.
   PubMedGoogle Scholar
• Judson MA, Hartung C, Byars T, Cox CE. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(1):51–57.
   PubMed Web of Science ®Google Scholar
• Milman N, Hanse A, et al. Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. APMIS. 2006;114(12):912–919.
   PubMed Web of Science ®Google Scholar
• Taylor RM, Gibson F, Donaldson N, Dhawan A. Study of the factors affecting health-related quality of life in adolescents after liver transplantation. Am J Transplant. 2009;9(5):1179–1188.
   PubMedGoogle Scholar
• Bonfioli AA. Sarcoidosis. Semin Ophthalmol. 2005;20(3):177–182.
   PubMedGoogle Scholar
• Jones NP. Sarcoidosis and uveitis. Ophthalmol Clin North Am. 2002;15(3):319–326.
   PubMedGoogle Scholar
• Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol. January 1, 2000;84(1):110–116.
   PubMedGoogle Scholar
• Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. Apr 1996;80(4):332–336.
   PubMed Web of Science ®Google Scholar
• Dana MR, Schaumberg DA, Foster CS. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology. 1996;103(11):1846–1853.
   PubMed Web of Science ®Google Scholar
• Maliarik MJ, Rybicki BA, Malvitz E, et al. Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. Am J Respir Crit Care Med. 1998;158(5):1566–1570.
   PubMedGoogle Scholar
• Evans M, Sharma O, LaBree L, Smith RE, Rao NA. Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis. Ophthalmology. 2007;114(2):325–333. e321.
   PubMedGoogle Scholar
• Chang B, Steimel J, Moller DR, et al. Depression in Sarcoidosis. Am J Respir Crit Care Med. 2001;163(2):329–334.
   PubMedGoogle Scholar
• Wirnsberger RM, De Vries J, Jansen TLTA, Van Heck GL, Wouters EFM, Drent M. Impairment of quality of life: rheumatoid arthritis versus sarcoidosis. The Netherlands Journal of Medicine. 1999;54(3):86–95.
   PubMedGoogle Scholar
• Schiffman RM, Whitcup SM. Visual functioning and general health status in patients with uveitis. Arch Ophthalmol. 2001;119(6):841–849.
   PubMedGoogle Scholar
• Department of Health and Human Services. Protection of human subjects; 2007.
   Google Scholar
• Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The Sarcoidosis Health Questionnaire: A new measure of Health-related Quality of Life. Am J Respir Crit Care Med. 2003;168(3):323–329.
   PubMedGoogle Scholar
• Mangione CM, Pitts J, Gutierrez P, Berry S, Hays RD. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998;116(11):1496–1504.
   PubMedGoogle Scholar
• Jabs DA, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Liu CC, Smith PL. Comparing time-accuracy curves: Beyond goodness-of-fit measures. Psychonomic Bulletin & Review. February 2009;16(1):190–203.
   Google Scholar
• Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-Related Quality of Life of persons with sarcoidosis. Chest. March 2004;125(3):997–1004.
   PubMedGoogle Scholar
• Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol. January 1, 2000;84(1):110–116.
   PubMedGoogle Scholar
• Yeager H RM, Baughman RP, Teirstein AS, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(2):147–153.
   PubMedGoogle Scholar
• Clemons TE CE, Bressler SB, McBee W, Age-elated Eye Disease Study Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Arch Ophthalmol. 2003;121(2):211–217.
   PubMedGoogle Scholar
• Klein R, Moss SE, Klein BE, Gutierrez P, Mangione CM. The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 2001;119(5):733–740.
   PubMedGoogle Scholar
• Cole SR, Beck RW, Moke PS, Gal RL, Long DT. The National Eye Institute Visual Function Questionnaire: Experience of the ONTT. Invest. Ophthalmol. Vis. Sci. April 1, 2000 2000;41(5):1017–1021.
   PubMedGoogle Scholar
• Parrish RK, II Gedde, SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol. November 1, 1997 1997;115(11):1447–1455.
   PubMedGoogle Scholar
• Nichols KK, Mitchell GL, Zadnik K. Performance and Repeatability of the NEI-VFQ-25 in patients with dry eye. Cornea. 2002;21(6):578–583.
   PubMedGoogle Scholar
• Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002;121(1):24–31.
   PubMedGoogle Scholar
• Judson MA, Thompson BW, Teirstein AS, Terrin ML, Rossman MD, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(3):204–211.
   PubMedGoogle Scholar
• Gibson GJ. Sarcoidosis: old and new treatments. Thorax. May 1, 2001;56(5):336–339.
   PubMedGoogle Scholar
• Guyatt GH, Feeny DH, Patrick DL. Measuring Health-related Quality of Life. Ann Intern Med. April 15, 1993;118(8):622–629.
   PubMedGoogle Scholar
• Jabs DA. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol. 1986;102(3):297–301.
   PubMedGoogle Scholar
• Khalatbari D, Stinnett S, McCallum RM, Jaffe GJ. Demographic-related variations in posterior segment ocular sarcoidosis. Ophthalmology. 2004;111(2):357–362.
   PubMedGoogle Scholar
• Rabin DL, Thompson B, Brown KM, et al. Sarcoidosis: social predictors of severity at presentation. Eur Respir J. October 1, 2004;24(4):601–608.
   PubMedGoogle Scholar
• Judson MA, Thompson BW, Teirstein AS, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(3):204–211.
   PubMedGoogle Scholar
• Rabin DL, Richardson MSA, Stein SR, Yeager H, Jr. Sarcoidosis severity and socioeconomic status. Eur Respir J. September 1, 2001; 18(3):499–506.
   PubMedGoogle Scholar